Luxturna granted six-month priority review by FDA.
Decision based on promising data from ongoing phase 1/2 trial.
Angionetics claims place among leaders in cardiovascular angiogenic gene therapy.
Study of nine patients produce encouraging results
Company will discuss next steps with FDA shortly
Philadelphia-based company could be frontrunner in gene therapy